{"id":"W4379791997","doi":"10.1200/jco.23.00233","title":"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Olaparib; Prostate cancer; Pembrolizumab; Oncology; Internal medicine; Randomized controlled trial; Biomarker; Open label; PARP inhibitor; Metastatic breast cancer; Cancer; Immunotherapy; Breast cancer; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001409152,0.001032511,0.001031297,0.0002142668,0.0003049135,0.0009793334,0.0006223939,0.0008244295,0.005082607],"category_scores_gemma":[0.00117559,0.0003613339,0.00092732,0.0002601562,0.0006187883,0.0009835811,0.0003337643,0.001949907,0.0008593955],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007453142,"about_ca_system_score_gemma":0.0009045286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000774116,"about_ca_topic_score_gemma":0.002431266,"domain_scores_codex":[0.99959,0.000226886,0.00002159634,0.00007720902,0.00003153263,0.00005277796],"domain_scores_gemma":[0.9995173,0.00008125303,0.0001368743,0.00002857041,0.00002670395,0.000209276],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9399841,0.006677974,0.00217023,0.00113126,0.0009780379,0.00006507924,0.0000745136,0.0006353487,0.004741441,0.0003221409,0.00312971,0.04009007],"study_design_scores_gemma":[0.9308647,0.05919392,0.005010613,0.0000864976,0.0005729027,0.0001133553,0.00003923122,0.0006123793,0.0005528573,0.0003120015,0.002623841,0.00001777508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724865,0.01413975,0.0006325595,0.001530085,0.0007093483,0.003456849,0.002165481,0.0001090421,0.004770385],"genre_scores_gemma":[0.9850379,0.004064156,0.001042147,0.001514876,0.0003975735,0.003024202,0.001692973,0.00002253706,0.003203761],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005082607,"threshold_uncertainty_score":0.017003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1857888830145629,"score_gpt":0.51321039237129,"score_spread":0.3274215093567271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}